Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

Covid19 Clinical Trial

— CimetrA  

Official title:

A Phase IIb, Double Blind, Placebo-controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05037162
• Other study ID #: MGC-009
• Status: Completed
• Phase: Phase 2
• Start date: October 11, 2022
• Est. completion date: March 1, 2023

Study information

• Verified date: March 2023
• Source: MGC Pharmaceuticals d.o.o
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multi-center multinational-controlled study in Israel, Brazil, Spain, and South-Africa.

240 adult patients who suffer from moderate COVID-19 infection. Safety will be assessed through collection and analysis of adverse events, blood and urine laboratory assessments and vital signs.

After Screening visit, the study drug will be administrated twice a day morning and evening (every 12 hours) during (day 1 and day 2) The patients will be randomized in 1:1:1 ratio to study drug (CimetrA) in two dosages in addition to Standard of Care - Arm 1, 2 or (Placebo) in addition to Standard of Care- Arm 3.

Description:

A preparation of CimertA (Botanical Drug), comprising Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, is proposed as a treatment for the disease associated with the novel corona virus SARS-CoV-2. This initiative is presented under the urgent circumstances of the fulminant pandemic caused by this lethal disease, which is known as COVID-19 and has spread across the globe causing death and disrupting the normal function of modern society. The grounds for the proposal are rooted in existing knowledge on the components and pharmacological features of this formulation and their relevance to the current understanding of the disease process being addressed.

The breakout of a lethal pneumonia in the city of Wuhan, China, towards the end of 2019, has led to the characterization of the new coronavirus related disease COVID-19. Its prominent features include a high rate of person-to-person transmission, a substantial risk of developing a lethal respiratory syndrome and potential failure of additional organs. Risk factors for a life-threatening clinical course have been identified, including advanced age and assorted comorbidities, such as cardiovascular disease, diabetes mellitus, hypertension, cancer. However, individuals devoid of any of the recognized risk factors are not immune to the severe manifestation of the disease and once infected carry a certain risk of mortality which has been calculated in Italy at circa 2%.

CoV is an enveloped, positive-sense single-stranded RNA (ss-RNA) virus belonging to the Coronaviridae family. The severe acute respiratory syndrome associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of COVID-19. Systemic proinflammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival.

SARS-CoV-2 activates the innate immune system and results in a release of a large number of cytokines, including IL-6, which can increase vascular permeability and cause a migration of fluid and blood cells into the alveoli as well as the consequent symptoms such as dyspnea and respiratory failure. The higher mortality is being linked to the result of ARDS (acute respiratory distress syndrome) aggravation and the tissue damage that can result in organ-failure and/or death.

Serum cytokine levels that are elevated in patients with Covid-19-associated cytokine storm include interleukin-1β, interleukin-6, IP-10, TNF, interferon-γ, macrophage inflammatory protein (MIP) 1α and 1β, and VEGF. Higher interleukin-6 levels are strongly associated with shorter survival. The relative frequencies of circulating activated CD4+ and CD8+ T cells and plasma blasts are increased in Covid-19. In addition to the elevated systemic cytokine levels and activated immune cells, several clinical and laboratory abnormalities, such as elevated CRP and d-dimer levels, hypoalbuminemia, renal dysfunction, and effusions, are also observed in Covid-19, as they are in cytokine storm disorders. Laboratory test results reflecting hyperinflammation and tissue damage were found to predict worsening outcomes in Covid-19.

CimetrA, comprising Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, was studied on patients with the novel corona virus SARS-CoV-2 in randomized double blind control Phase II study (MGC-006 - under a previous product name - ArtemiC). The study product demonstrated excellent safety and efficacy profiles.

In the in vitro clinical trial CimetrA demonstrated the ability to reduce cytokines elevation in PBMC induced cell tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: March 1, 2023
• Est. primary completion date: January 21, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Confirmed by PCR test SARS-CoV-2 infection (according to nationally authorized laboratory criteria)

2. Hospitalized patient with COVID-19 of moderate stable or worsening severity not requiring ICU admission (defined by NIH criteria - fever, cough, dyspnea, fast breathing, but no signs of severe pneumonia, including SpO2 = 94% on room air).

3. Age: 18 years old and above.

4. Subjects must be hospitalized

5. Ability to receive treatment by spray into the oral cavity

Exclusion Criteria:

1. Tube feeding or parenteral nutrition.

2. Patients with scores 5 or above per the Ordinal Scale for Clinical Improvement published by the WHO. (i.e., who need oxygen supply beyond use of nozzles or simple mask)

3. Need for admission to ICU during the present hospitalization at any time prior to completion of the recruitment to the study.

4. Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints.

Related Conditions & MeSH terms

• Corona Virus Infection
• Coronavirus Infections
• COVID-19
• Covid19
• Virus Diseases

Intervention

Diagnostic Test:
• Biochemistry blood test
preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
• Hematology blood test
preformed on days 1-14 and day 28. complete CBC.
• D-Dimer test (coagulation)
performed on days 1,2,7,14 and 28.
• Inflammatory markers
performed on days 1-7, 14 and 28. IL-6, IL-1ß, IL-12, TNF a, IFN-?
• Vital signs
performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
• VAS scale
performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
• WHO Ordinal Score
performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
• COVID-19-Related Symptoms assessment
performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
• COVID-19-Impact on Quality-of-Life Questionnaire
performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
• POST- COVID-19 Functional Status Scale:
performed on day 28. score: 0-3 ; a higher score indicates better recovery.
• Pregnancy test
performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
• Physical examination
performed on days 1-14 and day 28. a full examination by a doctor.
• PK parameters
performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain). The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below. For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)
• SARS-CoV-2 test (PCR)
performed on days 1,14 and 28.
• ECG
performed on days 1 and 28.

Drug:
• Treatment administration (twice a day)
performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)

Locations

Country	Name	City	State
Israel	Rambam Medical Center	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
MGC Pharmaceuticals d.o.o

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in WHO Ordinal Scale for clinical improvement	measured on days 1, 7, 14, 28 numerical value to assess the health status of the participant , scale is between 0-8 , The higher score means the worse outcome .	up to 28 days
Primary	Change in COVID-19-Related Symptoms score	measured on days 1,7, 14, 28 numerical value to assess the COVID-19-Related symptoms of participant scale is between 0-3, The higher score means the worse outcome .; score 0-3; higher score indicates worse outcome.	up to 28 days
Primary	Safety endpoint: will be assessed through collection and analysis of adverse events	Data management team will assess and review the AE's and SAE'S.	up to 28 days
Primary	Safety endpoint: will be assessed through collection and analysis of blood laboratory test.	Data management team will assess and review the lab test results (blood), assessment will be compared to the normal range. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition	up to 28 days
Primary	Safety endpoint: will be assessed through collection and analysis of urine laboratory test.	Data management team will assess and review the lab test results (urine), assessment will be compared to the normal range. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition	up to 28 days
Primary	Safety endpoint: will be assessed through collection and analysis of blood preasure	units: BPM (beats per minute) Data management team will assess and review the vital signs : blood pressure [mm Hg], saturation [%], body temperature [C] , Each category of the assessments will be compared to the normal ranges. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition	up to 28 days
Primary	Safety endpoint: will be assessed through collection and analysis of blood satturation	units: %O2 Data management team will assess and review the vital signs : blood pressure [mm Hg], saturation [%], body temperature [C] , Each category of the assessments will be compared to the normal ranges. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition	up to 28 days
Primary	Safety endpoint: will be assessed through collection and analysis of body temperature	units: celsius degrees Data management team will assess and review the vital signs : blood pressure [mm Hg], saturation [%], body temperature [C] , Each category of the assessments will be compared to the normal ranges. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition	up to 28 days
Secondary	Number of participants with depending on oxygen supplementation through day 28 since onset of symptoms		up to 28 days
Secondary	Change in inflammatory marker levels - IL-6, IL-1ß, IL-12, TNF a, IFN-?, CRP, NLR (Neutrophil / Lymphocyte ratio) at days 1, 2, 4, 7, compared to baseline		up to 7 days
Secondary	Pharmacokinetic profile of the study drug	Measurements : CMAX elimination rate constant (denoted as K) half-life (t 1/2) apparent volume of distribution (V d) total clearance rate (CL). AUC	on day 1 through 24 Hrs
Secondary	Pharmacokinetic profile of the study drug - maximal concentartion	CMAX measurement (mg/ml)	on day 1 through 24 Hrs
Secondary	Pharmacokinetic profile of the study drug - elimination rate constant (denoted as K)	(mg/ml/min)	on day 1 through 24 Hrs
Secondary	Pharmacokinetic profile of the study drug - half-life	half-life t 1/2 (Min)	on day 1 through 24 Hrs
Secondary	Pharmacokinetic profile of the study drug - apparent volume of distribution	apparent volume of distribution V d (mL)	on day 1 through 24 Hrs
Secondary	Pharmacokinetic profile of the study drug - total clearance rate	total clearance rate CL (min/mg)	on day 1 through 24 Hrs
Secondary	Pharmacokinetic profile of the study drug - AUC	AUC (min)	on day 1 through 24 Hrs
Secondary	duration of mechanical ventilation	in days	up to 28 days
Secondary	Incidence of Intensive Care Unit (ICU) stay during COVID-19 complication		up to 28 days
Secondary	Percentage of participants with definite or probable drug related adverse events		up to 28 days
Secondary	Long term adverse events of COVID-19 on Day 28	The Outcome will Measure the number of patients who recovered from covid_19 , but still have adverse events.	up to 28 days
Secondary	The Impact covid_19 on Quality of life of patients on Days 1, 14 and 28.	numerical value to assess the the impact of covid_19 on the quality life of the participant, scale is between 1-5, as expressed in the subject's subjective perception, The higher score is more important.	up to 28 days
Secondary	Course of change in D Dimer levels compared to baseline		up to 28 days
Secondary	Occurrence of secondary infections		up to 28 days
Secondary	Incidence of mechanical ventilation		up to 28 days